Cyanotech (CYAN)
OTHER OTC:CYAN
Top Page
Cyanotech
(OTC:CYAN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.28
▼(-20.57% Downside)
Action:ReiteratedDate:03/17/26
The score is driven primarily by weak financial performance (loss-making margins, high leverage, and negative operating cash flow) and bearish technicals (price below major moving averages and negative MACD). Valuation further pressures the score due to an exceptionally high P/E and no indicated dividend yield.
Positive Factors
Vertically integrated microalgae model
Cyanotech’s in-house cultivation and processing of Haematococcus and Spirulina gives control over yields, quality and supply. Vertical integration supports margin capture across the value chain, reduces supplier risk, and enables product differentiation that remains valuable over months.
Negative Factors
High leverage
A D/E of ~1.49 signals significant leverage that restricts financial flexibility. Over 2-6 months this raises refinancing and interest-rate exposure, limits capacity to invest in scale or R&D, and amplifies the impact of any revenue or yield setbacks on solvency and strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertically integrated microalgae model
Cyanotech’s in-house cultivation and processing of Haematococcus and Spirulina gives control over yields, quality and supply. Vertical integration supports margin capture across the value chain, reduces supplier risk, and enables product differentiation that remains valuable over months.
Read all positive factors
Cyanotech (CYAN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.14M
Dividend YieldN/A
Average Volume (3M)6.46K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth8.47%
EPS Growth68.88%
CountryUS
Employees77
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.03
Shares Outstanding7,392,243
10 Day Avg. Volume1,585
30 Day Avg. Volume6,463
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.28
Price to Sales (P/S)0.10
P/FCF Ratio-1.72
Enterprise Value/Market Cap6.28
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda14.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cyanotech Business Overview & Revenue Model
Company Description
Cyanotech Corporation (CYAN) is a biotechnology company based in Hawaii that specializes in the cultivation and processing of microalgae. Operating primarily in the nutritional supplements and specialty chemical sectors, Cyanotech produces high-qu...
How the Company Makes Money
Cyanotech makes money by growing microalgae at scale, harvesting it, and selling the resulting products through two primary revenue streams: (1) finished consumer products and (2) bulk ingredients. Finished consumer products include packaged dieta...
Cyanotech Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.27M | 24.21M | 23.07M | 23.18M | 35.97M | 32.34M |
| Gross Profit | 8.09M | 6.88M | 5.95M | 7.26M | 13.57M | 11.12M |
| EBITDA | 910.00K | -629.00K | -2.51M | -825.00K | 4.50M | 3.54M |
| Net Income | -1.78M | -3.20M | -5.27M | -3.44M | 2.15M | 920.00K |
Balance Sheet | ||||||
| Total Assets | 24.03M | 23.49M | 25.11M | 29.73M | 32.05M | 30.88M |
| Cash, Cash Equivalents and Short-Term Investments | 649.00K | 257.00K | 707.00K | 974.00K | 2.59M | 3.77M |
| Total Debt | 15.07M | 11.56M | 10.90M | 11.17M | 9.00M | 10.89M |
| Total Liabilities | 15.96M | 14.61M | 13.30M | 13.38M | 12.56M | 13.84M |
| Stockholders Equity | 8.06M | 8.88M | 11.81M | 16.35M | 19.49M | 17.04M |
Cash Flow | ||||||
| Free Cash Flow | -1.44M | -1.44M | -836.00K | -3.17M | 1.11M | 1.64M |
| Operating Cash Flow | -1.21M | -1.19M | -455.00K | -2.10M | 2.38M | 2.40M |
| Investing Cash Flow | -228.00K | -247.00K | -381.00K | -1.07M | -1.27M | -760.00K |
| Financing Cash Flow | 1.31M | 990.00K | 569.00K | 1.55M | -2.29M | -290.00K |
Cyanotech Technical Analysis
Negative
0.35
Price Trends
0.40
Negative
0.40
Negative
0.37
Negative
Market Momentum
-0.03
Positive
40.42
Neutral
35.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYAN, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.40, and below the 200-day MA of 0.37, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.42 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYAN.
Cyanotech Risk Analysis
Cyanotech disclosed 30 risk factors in its most recent earnings report. Cyanotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cyanotech Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $998.15M | 4.20 | 13.51% | ― | 8.33% | 47.71% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $413.88M | 22.99 | 12.18% | ― | 6.62% | -7.85% | |
53 Neutral | $318.94M | 33.56 | 2.03% | ― | 5.88% | -68.62% | |
50 Neutral | $24.08M | -7.20 | -14.36% | ― | 17.73% | -34.71% | |
45 Neutral | $58.29M | -0.21 | -111.73% | ― | -10.13% | -532.32% | |
42 Neutral | $2.14M | -3.62 | -31.37% | ― | 8.47% | 68.88% |
* Consumer Defensive Sector Average
CYAN
Cyanotech
0.29
-0.06
-17.14%
NATR
Nature's Sunshine Products
23.64
10.99
86.88%
SENEA
Seneca Foods
147.35
57.00
63.09%
HAIN
Hain Celestial
0.64
-3.47
-84.43%
USNA
USANA Health
17.28
-10.50
-37.80%
LSF
Laird Superfood
2.25
-4.03
-64.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.